Back to Search
Start Over
170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study
- Source :
- Immuno-Oncology and Technology. 16:100282
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Oncology
Immunology and Allergy
Subjects
Details
- ISSN :
- 25900188
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- Immuno-Oncology and Technology
- Accession number :
- edsair.doi...........c5893d68a11809371fd9a6eec3ca21d1
- Full Text :
- https://doi.org/10.1016/j.iotech.2022.100282